MabThera/Rituxan

Roche and AbbVie prepare to move Venclexta into first-line CLL

Gazyva is a follow-up to Roche’s big-selling Rituxan/MabThera (rituximab) anti-CD20 drug – a mainstay of CLL therapy given alongside chemotherapy – and was approved alongside chlorambucil for ... Venclexta is a key growth product for both companies

Roche’s new flu pill Xofluza approved in US

Roche is in need of a new set of innovative products, as its older generation of blockbusters, Avastin, Herceptin and MabThera/Rituxan come under competition from biosimilars.

Celgene to launch five new products through to 2020

Also on the agenda is a closer look at the AUGMENT trial of Revlimid with Roche’s Rituxan (rituximab) in relapsed/refractory indolent lymphoma.

Ocrevus surge keeps Roche smiling in Q3

As expected, biosimilar competition to two of its top products – MabThera and Herceptin – weighed heavy on Roche in the third quarter in Europe. ... 9% overall thanks to gains in the US, where it is sold as Rituxan, as well as international markets,

Encouraging data for Roche flu drug ahead of FDA decision

Roche is in need of a new set of innovative products, as its older generation of blockbusters, Avastin, Herceptin and MabThera/Rituxan come under competition from biosimilars.

[ Previous 5 results ] 2 3 4 5 6 7 8 9 10 11 [ Next 5 results ]